ReviewMucosal immunology2022
Lung microbial-host interface through the lens of multi-omics.
Review in Mucosal immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Microbial Signals in Cancer: Dissecting Host-Microbiota-Tumor Interactions and Potential Therapeutic Strategy.MedComm · 2026Review
- The respiratory microbiome: dynamics from health to disease.FEMS microbiology ecology · 2026Review
- Lower airway dysbiosis in nontuberculous mycobacteria-positive bronchiectasis is associated with neutrophil extracellular trap-predominant severe phenotypes.American journal of respiratory and critical care medicine · 2026Article
- Microbiome-innate immune crosstalk in acute exacerbation of idiopathic pulmonary fibrosis: an amplification framework.Frontiers in immunology · 2026Review
- The airway epithelial-immune axis: mechanisms and therapeutic implications.Frontiers in immunology · 2026Review
- The emerging role of microbiota in lung cancer: a new perspective on lung cancer development and treatment.Cellular oncology (Dordrecht, Netherlands) · 2025Review
- Microbial biomarker development for detection and prognosis of early-stage non-small cell lung cancer.Cancer biomarkers : section A of Disease markers · 2025Review
- The significance of periostin in the diagnosis of idiopathic pulmonary fibrosis and prediction of acute exacerbations.Journal of thoracic disease · 2025Article
- The Microbiome in Asthma Heterogeneity: The Role of Multi-Omic Investigations.Immunological reviews · 2025Review
- Microbiome and metabolome patterns after lung transplantation reflect underlying disease and chronic lung allograft dysfunction.Microbiome · 2024Article
- Review
- Does "all disease begin in the gut"? The gut-organ cross talk in the microbiome.Applied microbiology and biotechnology · 2024Review
- Multi-omics integration reveals a nonlinear signature that precedes progression of lung fibrosis.Clinical & translational immunology · 2024Article
- Symbiotic microbial communities in various locations of the lung cancer respiratory tract along with potential host immunological processes affected.Frontiers in cellular and infection microbiology · 2024Review
- Longitudinal microbial and molecular dynamics in the cystic fibrosis lung after Elexacaftor-Tezacaftor-Ivacaftor therapy.Respiratory research · 2023Article
- Longitudinal Microbial and Molecular Dynamics in the Cystic Fibrosis Lung after Elexacaftor-Tezacaftor-Ivacaftor therapy.Research square · 2023Article
- The dynamic lung microbiome in health and disease.Nature reviews. Microbiology · 2023Review
- Applying Next-Generation Sequencing and Multi-Omics in Chronic Obstructive Pulmonary Disease.International journal of molecular sciences · 2023Review
- Airway microbiome-immune crosstalk in chronic obstructive pulmonary disease.Frontiers in immunology · 2022Review
- Health expenditures, environmental quality, and economic development: State-of-the-art review and findings in the context of COP26.Frontiers in public health · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
In recent years, our understanding of the microbial world within us has been revolutionized by the use of culture-independent techniques. The use of multi-omic approaches can now not only comprehensively characterize the microbial environment but also evaluate its functional aspects and its relationship with the host immune response. Advances in bioinformatics have enabled high throughput and in-depth analyses of transcripts, proteins and metabolites and enormously expanded our understanding of the role of the human microbiome in different conditions. Such investigations of the lower airways have specific challenges but as the field develops, new approaches will be facilitated. In this review, we focus on how integrative multi-omics can advance our understanding of the microbial environment and its effects on the host immune tone in the lungs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.